首页> 外国专利> Microcapsule preparation based on chitosan alginate-acyl derivatives, its preparation and use

Microcapsule preparation based on chitosan alginate-acyl derivatives, its preparation and use

机译:基于壳聚糖藻酸盐-酰基衍生物的微胶囊制剂及其制备和用途

摘要

1. A microcapsule preparation based on alginate-acyl derivatives of chitosan obtained by mixing microcapsules from alginate-acyl derivatives of chitosan with an aqueous solution, where the structure of the microcapsule consists of two parts: the membrane of the microcapsule and the inner core; the microcapsule membrane is a polyelectrolyte composite hydrogel membrane formed by chitosan, alginates and acyl derivatives of chitosan, and the inner core is an alginate liquid or hydrogel medium containing cells. 2. The microcapsule preparation according to claim 1, characterized in that the microcapsules in the preparation are spherical microcapsules with a particle size of from 10 to 2000 microns; the thickness of the membrane is from 0.1 to 100 μm, and the molecular weight of the alginate forming the membrane is from 10 kDa to 2000 kDa; chitosan material has a deacetylation degree of from 70 to 98% and a molecular weight of 1 kDa to 500 kDa; the molecular weight of the acyl derivatives of chitosan is from 1 kDa to 800 kDa; the mass ratio of chitosan, alginate and acyl derivatives of chitosan is from 0: 1: 0.1 to 10: 1: 10; and the concentration of alginate in the core is from 0.1 to 50 g / l. 3. The microcapsule preparation according to claim 1 or 2, characterized in that in the preparation the acyl derivatives of chitosan in the microcapsule are N-acyl chitosan with the monomeric structure shown below: where R is formyl, acetyl, propionyl, butyryl, valeryl or caproyl; the degree of substitution of acyl derivatives is from 10 to 60%; the molecular weight of the chitosan frame material is from 1 to 400 kDa; and the degree of deacetylation is
机译:1.一种基于壳聚糖的藻酸酯-酰基衍生物的微胶囊制剂,其是通过将来自壳聚糖的藻酸酯-酰基衍生物的微胶囊与水溶液混合而获得的,其中,微胶囊的结构由两部分组成:微胶囊的膜和内核。微胶囊膜是由壳聚糖,藻酸盐和壳聚糖的酰基衍生物形成的聚电解质复合水凝胶膜,内核是含有细胞的藻酸盐液体或水凝胶介质。 2.根据权利要求1所述的微胶囊制剂,其特征在于,所述制剂中的微胶囊是粒径为10至2000微米的球形微胶囊;优选地,所述微胶囊为球形。膜的厚度为0.1至100μm,形成膜的藻酸盐的分子量为10kDa至2000kDa。壳聚糖材料的脱乙酰度为70-98%,分子量为1kDa-500kDa。壳聚糖的酰基衍生物的分子量为1kDa至800kDa。壳聚糖,藻酸盐和壳聚糖的酰基衍生物的质量比为0∶1∶0.1至10∶1∶10。核心中的藻酸盐浓度为0.1至50 g / l。 3.根据权利要求1或2所述的微胶囊制剂,其特征在于,在所述微胶囊中,壳聚糖的酰基衍生物是具有如下所示的单体结构的N-酰基壳聚糖:其中R是甲酰基,乙酰基,丙酰基,丁酰基,戊酰基。或己酰;酰基衍生物的取代度为10-60%。壳聚糖骨架材料的分子量为1至400kDa。脱乙酰度为

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号